Outlook Therapeutics Inc (NASDAQ:OTLK) does about 1.58M shares in volume on a normal day but saw 859167 shares change hands in the recent trading day. The company now has a market cap of 38.08M USD. Its current market price is $1.61, marking a decrease of -5.29% compared to the previous close of $1.70. The 52 week high reached by this stock is $12.85 whilst the lowest price level in 52 weeks is $0.87.
Outlook Therapeutics Inc (OTLK) has a 20-day trading average at $3.7170 and the current price is -87.47% off the 52-week high compared with 85.06% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.8252 and its 200-day simple moving average is $7.0094. If we look at the stock’s price movements over the week, volatility stands at 15.70%, which increases to 17.49% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 20.75 to suggest the stock is oversold.
The consensus objective for the share price is $29.50, suggesting that the stock has a potential upside of 94.54% over the period.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 5 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
BTIG Research upgraded the stock to “Buy” from Neutral on March 27, 2024 at a price target of $50. Chardan Capital Markets upgraded its price target at $3.
The current price level is -56.69%, -66.63%, and -77.03% away from its SMA20, SMA50, and SMA200 respectively, with the OTLK price moving above the 50-day SMA on current market day. Outlook Therapeutics Inc (OTLK) stock is down -10.80% over the week and -74.53% over the past month. Its price is -79.57% year-to-date and -81.12% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.9 and -4.01 for whole year.
To reach the target analysts have set, the stock logically needs to grow 94.54 percent from here.
Outstanding shares total 23.41M with insiders holding 35.58% of the shares and institutional holders owning 35.65% of the company’s common stock. The beta has a value of 0.53.
